| Cardiovascular events and intensity of treatment in polycythemia vera R Marchioli, G Finazzi, G Specchia, R Cacciola, R Cavazzina, D Cilloni, ... New England Journal of Medicine 368 (1), 22-33, 2013 | 963 | 2013 |
| Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid … A Rambaldi, A Grassi, A Masciulli, C Boschini, MC Micò, B Bruno, ... The lancet oncology 16 (15), 1525-1536, 2015 | 196 | 2015 |
| Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis P Guglielmelli, G Barosi, A Rambaldi, R Marchioli, A Masciulli, L Tozzi, ... Blood, The Journal of the American Society of Hematology 118 (8), 2069-2076, 2011 | 181 | 2011 |
| Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis A Carobbio, A Ferrari, A Masciulli, A Ghirardi, G Barosi, T Barbui Blood advances 3 (11), 1729-1737, 2019 | 149 | 2019 |
| White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study T Barbui, A Masciulli, MR Marfisi, G Tognoni, G Finazzi, A Rambaldi, ... Blood, The Journal of the American Society of Hematology 126 (4), 560-561, 2015 | 115 | 2015 |
| Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial T Barbui, AM Vannucchi, V De Stefano, A Masciulli, A Carobbio, A Ferrari, ... The Lancet Haematology 8 (3), e175-e184, 2021 | 109 | 2021 |
| Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study F Raimondi, L Novelli, A Ghirardi, FM Russo, D Pellegrini, R Biza, ... BMC pulmonary medicine 21, 1-11, 2021 | 107 | 2021 |
| Achieving molecular remission before allogeneic stem cell transplantation in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: impact on … F Lussana, T Intermesoli, F Gianni, C Boschini, A Masciulli, O Spinelli, ... Biology of Blood and Marrow Transplantation 22 (11), 1983-1987, 2016 | 93 | 2016 |
| High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib T Barbui, AM Vannucchi, A Alvarez-Larran, A Iurlo, A Masciulli, ... Leukemia 35 (2), 485-493, 2021 | 90 | 2021 |
| Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas S Cortelazzo, C Tarella, AM Gianni, M Ladetto, AM Barbui, A Rossi, ... Journal of Clinical Oncology 34 (33), 4015-4022, 2016 | 86 | 2016 |
| The CYTO‐PV: A Large‐Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera R Marchioli, G Finazzi, G Specchia, A Masciulli, MR Mennitto, T Barbui Thrombosis 2011 (1), 794240, 2011 | 86 | 2011 |
| Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study T Barbui, A Ghirardi, A Masciulli, A Carobbio, F Palandri, N Vianelli, ... Leukemia 33 (8), 1996-2005, 2019 | 85 | 2019 |
| A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: a propensity‐matched study T Barbui, AM Vannucchi, G Finazzi, MC Finazzi, A Masciulli, A Carobbio, ... American journal of hematology 92 (11), 1131-1136, 2017 | 81 | 2017 |
| Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms DRJ Arachchillage, M Laffan Seminars in Thrombosis and Hemostasis 45 (06), 604-611, 2019 | 60 | 2019 |
| Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the … MT Voso, G Leone, A Piciocchi, L Fianchi, S Santarone, A Candoni, ... Annals of Oncology 28 (7), 1547-1553, 2017 | 60 | 2017 |
| Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms L Pieri, C Paoli, U Arena, F Marra, F Mori, M Zucchini, S Colagrande, ... American journal of hematology 92 (2), 187-195, 2017 | 58 | 2017 |
| Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis A Masciulli, A Ferrari, A Carobbio, A Ghirardi, T Barbui Blood advances 4 (2), 380-386, 2020 | 56 | 2020 |
| Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera A Carobbio, AM Vannucchi, V De Stefano, A Masciulli, P Guglielmelli, ... Blood cancer journal 12 (2), 28, 2022 | 47 | 2022 |
| Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study P Guglielmelli, A Ghirardi, A Carobbio, A Masciulli, C Maccari, B Mora, ... Blood Advances 6 (2), 373-375, 2022 | 45 | 2022 |
| Second cancers in MPN: Survival analysis from an international study M Marchetti, A Ghirardi, A Masciulli, A Carobbio, F Palandri, N Vianelli, ... American journal of hematology 95 (3), 295-301, 2020 | 43 | 2020 |
